Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,682 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | recruiting | Phase 1 | 190 | Immunome, Inc.INDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT06840834 |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy(Bi-MAPS) |
| recruiting |
| Phase 2 |
| 38 |
| Intergroupe Francophone de Cancerologie ThoraciqueOTHER |
| 1 |
| Aug 10, 2026 |
| clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT07412028 | Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)(ANDROLIPO) | recruiting | N/A | 81 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT05999994 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer(CAMPFIRE) | recruiting | Phase 2 | 105 | Eli Lilly and CompanyINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT07173829 | A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression(BORDEAUX-GLIO) | recruiting | — | 45 | University Hospital, BordeauxOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07380672 | IMpact of Mind-body Therapies (HYpnosis and Relaxation) on Anxiety in Children, Adolescents and Young Adults Who Had Been Treated in ONcology. Multicenter Study.(HARMONY-Impact) | recruiting | N/A | 558 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753343 | Identification and Description of Patients With High-risk Non Metastatic RCC(HIROES) | recruiting | — | 6,109 | University Hospital, BordeauxOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05232916 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects(FLAMINGO-01) | recruiting | Phase 3 | 2,250 | Greenwich LifeSciences, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT04794075 | Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer(ETAPH) | recruiting | N/A | 300 | Centre Hospitalier Emile RouxOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | recruiting | Phase 1 / Phase 2 | 680 | Daiichi SankyoINDUSTRY | 18 | Aug 5, 2026 | clinicaltrials |
| NCT07483983 | Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance(UNLOCK ASP3082) | recruiting | Phase 2 | 60 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06476184 | Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery(SALVOVAR) | recruiting | Phase 3 | 250 | ARCAGY/ GINECO GROUPOTHER | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06552091 | Guided Digital Self-Hypnosis Solution for Managing Hot Flashes in Patients Undergoing Adjuvant Hormone Therapy(HYBOU) | recruiting | N/A | 76 | Institut de Cancérologie de LorraineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT06923774 | European Real-World Registry for Use of the Ion Endoluminal System | recruiting | — | 1,200 | Intuitive SurgicalINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06960577 | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 7 | Aug 4, 2026 | clinicaltrials |
| NCT04746729 | Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy(HARMONIC-RT) | recruiting | — | 2,670 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 4 | Aug 3, 2026 | clinicaltrials |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 307 | Xencor, Inc.INDUSTRY | 5 | Aug 3, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT07280416 | Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer(INDICA) | recruiting | — | 260 | Centre Hospitalier Emile RouxOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT04747054 | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers(PembroMetaRT) | recruiting | Phase 3 | 102 | UNICANCEROTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06625970 | Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse(PEACE 7) | recruiting | Phase 3 | 700 | UNICANCEROTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07106632 | Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests(OPTIMA-YOUNG) | recruiting | Phase 3 | 3,380 | UNICANCEROTHER | 7 | Jul 31, 2026 | clinicaltrials |
| NCT07117058 | Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.(HARMONY-Tool) | recruiting | — | 545 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07295457 | Clinical Trial Evaluating the Efficacy and Implementation of an Early Adapted Physical Activity to Prevent and Manage Aromatase Inhibitor-induced Musculoskeletal Pain in Breast Cancer (APIS)(APIS) | recruiting | N/A | 182 | Hospices Civils de LyonOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739121 | Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations(BEACON) | recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT01620372 | French Childhood Cancer Survivor Study(FCCSS) | recruiting | — | 18,000 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma(GBM AGILE) | recruiting | Phase 2 / Phase 3 | 2,250 | Global Coalition for Adaptive ResearchOTHER | 6 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT06486883 | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype(PONTIAC) | recruiting | Phase 2 | 200 | MedSIROTHER | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07094113 | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 434 | AmgenINDUSTRY | 14 | Jul 30, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT07300631 | SpaceOAR Post-Market Registry Study(OASIS) | recruiting | — | 320 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT02029001 | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment(MOST plus) | recruiting | Phase 2 | 900 | Centre Leon BerardOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT06675604 | LEOPARD Training and Validation Data Collection Study(LEOPARD TVDCS) | recruiting | — | 4,500 | Assistance Publique - Hôpitaux de ParisOTHER | 7 | Jul 29, 2026 | clinicaltrials |
| NCT06723275 | LEOPARD Prospective Validation Cohort 1(LEOPARD PVC1) | recruiting | — | 630 | Assistance Publique - Hôpitaux de ParisOTHER | 5 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 | clinicaltrials |
| NCT06627595 | Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management(APiTOXMM) | recruiting | — | 160 | University Hospital, MontpellierOTHER | 1 | Jul 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials